Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-10-14
2009-11-10
Coleman, Brenda L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S235800, C514S252110, C514S253090, C514S253100, C514S253120, C544S060000, C544S120000, C544S357000, C544S360000, C544S364000
Reexamination Certificate
active
07615550
ABSTRACT:
The present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders including Alzheimer's disease.
REFERENCES:
patent: 3996361 (1976-12-01), Friebe et al.
patent: 4405620 (1983-09-01), Buckle et al.
patent: 5364791 (1994-11-01), Vegeto et al.
patent: 5874534 (1999-02-01), Vegeto et al.
patent: 5880128 (1999-03-01), Doll et al.
patent: 5935934 (1999-08-01), Vegeto et al.
patent: 2002/0137931 (2002-09-01), Bennani et al.
patent: 2006/0019964 (2006-01-01), Ancliff et al.
patent: 4410822 (1995-09-01), None
patent: 2002-173426 (2002-06-01), None
patent: WO 95/25443 (1995-09-01), None
patent: WO 97/26252 (1997-07-01), None
patent: WO 99/41242 (1999-08-01), None
patent: 0206223 (2002-01-01), None
patent: WO 02 06233 (2002-01-01), None
patent: WO 02 12190 (2002-02-01), None
patent: WO 02 12214 (2002-02-01), None
patent: 02055496 (2002-07-01), None
patent: WO 02 076925 (2002-10-01), None
patent: WO 03 059341 (2003-07-01), None
patent: WO 03 066604 (2003-08-01), None
patent: WO 2004/094441 (2004-11-01), None
Leurs et al., Trends Pharmacol. Sci. 19:177-183 (1998).
Schlicker et al., Fundam. Clin. Pharmacol. 8:128-137 (1994).
Onodera et al., In: The Histamine H3 Receptor, ed Leurs and Timmerman, pp. 255-267, Elsevier Science B.V. (1998).
Giovanni et al., Behav. Brain Res. 104:147-155 (1999).
Hill et al., Pharmacol. Rev. 49:253-278 (1997).
Aaronson, Ann. Allergy 67:541-547 (1991).
Varty & Hey, Eur. J. Pharmacol. 452:339-345 (2002).
Hey et al., Arzneim-Forsch Drug Res. 48:881-888 (1998).
McLeod et al., Am. J. Rhinol. 13:391-399 (1999).
Chem. Pharm. Bull, 49(10):1314 (2001) (Abstract).
Lovenberg et al., Mol. Pharmacol. 55:1101-1107 (1999).
Taylor-Clark, et al., “Histamine receptors that influence blockage of the normal human nasal airway.” British Journal of Pharmacology, 2005, vol. 144, pp. 867-874.
Varty, et al. “Activiation of histamine H3 receptors in human nasal mucosa inhibits sympathetic vasoconstriction.” European Journal of Pharmacology, 2004, vol. 484, pp. 83-89.
Heightman Thomas Daniel
Hodgson Simon Teanby
Lindon Matthew J
Wilson David Matthew
Coleman Brenda L
Glaxo Group Limited
Riek James P.
LandOfFree
Substituted piperazines,(1,4) diazepines, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted piperazines,(1,4) diazepines, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted piperazines,(1,4) diazepines, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4056718